CN111406737B - 用于器官持续维持的成分、装置和方法 - Google Patents
用于器官持续维持的成分、装置和方法 Download PDFInfo
- Publication number
- CN111406737B CN111406737B CN202010332040.1A CN202010332040A CN111406737B CN 111406737 B CN111406737 B CN 111406737B CN 202010332040 A CN202010332040 A CN 202010332040A CN 111406737 B CN111406737 B CN 111406737B
- Authority
- CN
- China
- Prior art keywords
- hemoglobin
- sodium
- perfusion
- injection
- perfusate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000056 organ Anatomy 0.000 title claims abstract description 325
- 239000000203 mixture Substances 0.000 title claims abstract description 138
- 238000000034 method Methods 0.000 title claims abstract description 104
- 238000012423 maintenance Methods 0.000 title abstract description 8
- 230000010412 perfusion Effects 0.000 claims abstract description 256
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 75
- 239000001301 oxygen Substances 0.000 claims abstract description 75
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 75
- 238000004321 preservation Methods 0.000 claims abstract description 38
- 102000001554 Hemoglobins Human genes 0.000 claims description 787
- 108010054147 Hemoglobins Proteins 0.000 claims description 784
- 239000007924 injection Substances 0.000 claims description 264
- 238000002347 injection Methods 0.000 claims description 264
- 239000000243 solution Substances 0.000 claims description 233
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 220
- 238000000108 ultra-filtration Methods 0.000 claims description 152
- 239000007788 liquid Substances 0.000 claims description 137
- -1 compound amino acid Chemical class 0.000 claims description 126
- 239000012528 membrane Substances 0.000 claims description 124
- 210000004369 blood Anatomy 0.000 claims description 121
- 239000008280 blood Substances 0.000 claims description 121
- 238000005086 pumping Methods 0.000 claims description 112
- 239000011780 sodium chloride Substances 0.000 claims description 107
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 100
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 94
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 claims description 93
- 229960003016 cefoxitin sodium Drugs 0.000 claims description 93
- 210000003743 erythrocyte Anatomy 0.000 claims description 88
- 229940024606 amino acid Drugs 0.000 claims description 80
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 70
- 238000006213 oxygenation reaction Methods 0.000 claims description 66
- 241000282414 Homo sapiens Species 0.000 claims description 65
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 63
- 239000008103 glucose Substances 0.000 claims description 61
- 229920000669 heparin Polymers 0.000 claims description 61
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims description 60
- 229960001008 heparin sodium Drugs 0.000 claims description 60
- 102000007456 Peroxiredoxin Human genes 0.000 claims description 52
- 108030002458 peroxiredoxin Proteins 0.000 claims description 52
- 239000012510 hollow fiber Substances 0.000 claims description 48
- 229940088594 vitamin Drugs 0.000 claims description 48
- 239000011782 vitamin Substances 0.000 claims description 48
- 235000013343 vitamin Nutrition 0.000 claims description 48
- 229930003231 vitamin Natural products 0.000 claims description 48
- 102000004877 Insulin Human genes 0.000 claims description 47
- 108090001061 Insulin Proteins 0.000 claims description 47
- 229940125396 insulin Drugs 0.000 claims description 47
- 239000000126 substance Substances 0.000 claims description 47
- 238000002054 transplantation Methods 0.000 claims description 43
- 239000012530 fluid Substances 0.000 claims description 41
- 238000001914 filtration Methods 0.000 claims description 40
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 38
- 210000004185 liver Anatomy 0.000 claims description 37
- 230000000694 effects Effects 0.000 claims description 36
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 35
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 35
- 239000001509 sodium citrate Substances 0.000 claims description 35
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 35
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 34
- 230000004087 circulation Effects 0.000 claims description 34
- 239000007983 Tris buffer Substances 0.000 claims description 33
- 239000007789 gas Substances 0.000 claims description 30
- 239000011261 inert gas Substances 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 28
- 229920000642 polymer Polymers 0.000 claims description 27
- 238000005406 washing Methods 0.000 claims description 26
- 230000008569 process Effects 0.000 claims description 25
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 24
- 238000006116 polymerization reaction Methods 0.000 claims description 24
- 210000002216 heart Anatomy 0.000 claims description 22
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 20
- 108010064719 Oxyhemoglobins Proteins 0.000 claims description 20
- 238000010828 elution Methods 0.000 claims description 20
- 238000000338 in vitro Methods 0.000 claims description 20
- 239000008055 phosphate buffer solution Substances 0.000 claims description 19
- 210000004204 blood vessel Anatomy 0.000 claims description 18
- 238000005571 anion exchange chromatography Methods 0.000 claims description 17
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 16
- 210000003734 kidney Anatomy 0.000 claims description 16
- 230000001954 sterilising effect Effects 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 15
- 239000012279 sodium borohydride Substances 0.000 claims description 15
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 15
- 231100000331 toxic Toxicity 0.000 claims description 15
- 230000002588 toxic effect Effects 0.000 claims description 15
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 claims description 12
- 239000001103 potassium chloride Substances 0.000 claims description 12
- 235000011164 potassium chloride Nutrition 0.000 claims description 12
- 238000000889 atomisation Methods 0.000 claims description 11
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 claims description 11
- 229940052299 calcium chloride dihydrate Drugs 0.000 claims description 11
- 238000007865 diluting Methods 0.000 claims description 11
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 11
- 210000004072 lung Anatomy 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 10
- 239000001569 carbon dioxide Substances 0.000 claims description 10
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 10
- 150000003384 small molecules Chemical class 0.000 claims description 7
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000004891 communication Methods 0.000 claims description 6
- 239000012460 protein solution Substances 0.000 claims description 6
- 239000001540 sodium lactate Substances 0.000 claims description 6
- 235000011088 sodium lactate Nutrition 0.000 claims description 6
- 229940005581 sodium lactate Drugs 0.000 claims description 6
- 230000001502 supplementing effect Effects 0.000 claims description 6
- 239000008156 Ringer's lactate solution Substances 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 3
- 230000000717 retained effect Effects 0.000 claims description 3
- 230000006870 function Effects 0.000 abstract description 11
- 235000001014 amino acid Nutrition 0.000 description 68
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 66
- 239000002158 endotoxin Substances 0.000 description 46
- 238000009472 formulation Methods 0.000 description 38
- 210000001519 tissue Anatomy 0.000 description 37
- 239000003795 chemical substances by application Substances 0.000 description 29
- 238000001990 intravenous administration Methods 0.000 description 28
- 108010061951 Methemoglobin Proteins 0.000 description 27
- 239000003814 drug Substances 0.000 description 27
- 210000004379 membrane Anatomy 0.000 description 25
- 206010021143 Hypoxia Diseases 0.000 description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 description 20
- 150000001413 amino acids Chemical group 0.000 description 20
- 150000007523 nucleic acids Chemical group 0.000 description 20
- 208000007502 anemia Diseases 0.000 description 19
- 239000008194 pharmaceutical composition Substances 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 19
- 230000008859 change Effects 0.000 description 18
- 230000007954 hypoxia Effects 0.000 description 18
- 238000001802 infusion Methods 0.000 description 18
- 238000001514 detection method Methods 0.000 description 17
- 239000000539 dimer Substances 0.000 description 15
- 230000001413 cellular effect Effects 0.000 description 14
- 230000002440 hepatic effect Effects 0.000 description 14
- 210000005260 human cell Anatomy 0.000 description 14
- 241000283690 Bos taurus Species 0.000 description 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 13
- 230000003068 static effect Effects 0.000 description 13
- 238000011144 upstream manufacturing Methods 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 238000007789 sealing Methods 0.000 description 12
- 102100033902 Endothelin-1 Human genes 0.000 description 11
- 101800004490 Endothelin-1 Proteins 0.000 description 11
- 230000001276 controlling effect Effects 0.000 description 11
- 230000006378 damage Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 229940021013 electrolyte solution Drugs 0.000 description 10
- 239000008151 electrolyte solution Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 238000005520 cutting process Methods 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 230000003647 oxidation Effects 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- 241000282341 Mustela putorius furo Species 0.000 description 8
- 241000283984 Rodentia Species 0.000 description 8
- 210000002767 hepatic artery Anatomy 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- 241000729176 Fagopyrum dibotrys Species 0.000 description 7
- 150000001299 aldehydes Chemical class 0.000 description 7
- 238000003306 harvesting Methods 0.000 description 7
- 229910052742 iron Inorganic materials 0.000 description 7
- 239000000082 organ preservation Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 241000272201 Columbiformes Species 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 241000282887 Suidae Species 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 239000003792 electrolyte Substances 0.000 description 6
- 239000007943 implant Substances 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 239000012669 liquid formulation Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000000379 polymerizing effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 230000000087 stabilizing effect Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 210000001631 vena cava inferior Anatomy 0.000 description 6
- 239000002699 waste material Substances 0.000 description 6
- 241000251468 Actinopterygii Species 0.000 description 5
- 241000283153 Cetacea Species 0.000 description 5
- 206010018910 Haemolysis Diseases 0.000 description 5
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 5
- 241000270322 Lepidosauria Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 239000003633 blood substitute Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 150000003278 haem Chemical group 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 208000028867 ischemia Diseases 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 230000002934 lysing effect Effects 0.000 description 5
- 210000000107 myocyte Anatomy 0.000 description 5
- 230000000149 penetrating effect Effects 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 210000003240 portal vein Anatomy 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 239000006004 Quartz sand Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 239000000815 hypotonic solution Substances 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 230000002572 peristaltic effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 229960002668 sodium chloride Drugs 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 208000032467 Aplastic anaemia Diseases 0.000 description 3
- 208000000412 Avitaminosis Diseases 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 208000035202 High altitude pulmonary edema Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010021135 Hypovitaminosis Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 3
- 206010029155 Nephropathy toxic Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000002933 Thioredoxin Human genes 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 210000002376 aorta thoracic Anatomy 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 239000012537 formulation buffer Substances 0.000 description 3
- 102000018146 globin Human genes 0.000 description 3
- 108060003196 globin Proteins 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 208000034737 hemoglobinopathy Diseases 0.000 description 3
- 208000007475 hemolytic anemia Diseases 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000001146 hypoxic effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000007694 nephrotoxicity Effects 0.000 description 3
- 231100000417 nephrotoxicity Toxicity 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 108010001073 oxyhemoglobin oxidase Proteins 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 208000007056 sickle cell anemia Diseases 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229920001169 thermoplastic Polymers 0.000 description 3
- 239000004416 thermosoftening plastic Substances 0.000 description 3
- 108060008226 thioredoxin Proteins 0.000 description 3
- 229940094937 thioredoxin Drugs 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 208000030401 vitamin deficiency disease Diseases 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000010750 Metalloproteins Human genes 0.000 description 2
- 108010063312 Metalloproteins Proteins 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 235000017343 Quebracho blanco Nutrition 0.000 description 2
- 241000065615 Schinopsis balansae Species 0.000 description 2
- 206010049771 Shock haemorrhagic Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 150000001642 boronic acid derivatives Chemical class 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 108010002255 deoxyhemoglobin Proteins 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 230000010437 erythropoiesis Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 108010036302 hemoglobin AS Proteins 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 210000002417 xiphoid bone Anatomy 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108010044267 Abnormal Hemoglobins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 101100243025 Arabidopsis thaliana PCO2 gene Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035049 Blood-Borne Infections Diseases 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 102000016899 Cytochrome-B(5) Reductase Human genes 0.000 description 1
- 108010028689 Cytochrome-B(5) Reductase Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013886 Dysaesthesia Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010030158 HBOC 201 Proteins 0.000 description 1
- 108010050026 HBOC 301 Proteins 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 1
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241001481166 Nautilus Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 201000010183 Papilledema Diseases 0.000 description 1
- 206010033712 Papilloedema Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 208000013544 Platelet disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010043395 Thalassaemia sickle cell Diseases 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 201000001383 blood group incompatibility Diseases 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000015322 bone marrow disease Diseases 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 210000001953 common bile duct Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000003635 deoxygenating effect Effects 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- TXKMVPPZCYKFAC-UHFFFAOYSA-N disulfur monoxide Inorganic materials O=S=S TXKMVPPZCYKFAC-UHFFFAOYSA-N 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000013627 low molecular weight specie Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000005135 methemoglobinemia Diseases 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000007183 paleface Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005451 protein repair Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000013138 pruning Methods 0.000 description 1
- 210000004061 pubic symphysis Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011110 re-filtration Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 210000002796 renal vein Anatomy 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical compound S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000287 tissue oxygenation Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000002620 vena cava superior Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000002912 waste gas Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0236—Mechanical aspects
- A01N1/0242—Apparatuses, i.e. devices used in the process of preservation of living parts, such as pumps, refrigeration devices or any other devices featuring moving parts and/or temperature controlling components
- A01N1/0247—Apparatuses, i.e. devices used in the process of preservation of living parts, such as pumps, refrigeration devices or any other devices featuring moving parts and/or temperature controlling components for perfusion, i.e. for circulating fluid through organs, blood vessels or other living parts
Landscapes
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Thermal Sciences (AREA)
- Mechanical Engineering (AREA)
- Health & Medical Sciences (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims (28)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010332040.1A CN111406737B (zh) | 2020-04-24 | 2020-04-24 | 用于器官持续维持的成分、装置和方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010332040.1A CN111406737B (zh) | 2020-04-24 | 2020-04-24 | 用于器官持续维持的成分、装置和方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111406737A CN111406737A (zh) | 2020-07-14 |
CN111406737B true CN111406737B (zh) | 2021-11-19 |
Family
ID=71485731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010332040.1A Active CN111406737B (zh) | 2020-04-24 | 2020-04-24 | 用于器官持续维持的成分、装置和方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111406737B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023196521A1 (en) * | 2022-04-06 | 2023-10-12 | Ohio State Innovation Foundation | Oxygen carriers for maintaining organ viability during normothermic perfusion |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3061633B1 (fr) * | 2017-01-09 | 2019-05-31 | Universite De Franche Comte | Dispositif et procede de conservation et de transport d'au moins un tissu humain ou animal en vue d'une greffe ou d'une experience ex vivo |
CN112273373B (zh) * | 2020-10-29 | 2022-06-07 | 无锡市人民医院 | 离体肺脏机械灌注液及其制备方法和应用 |
CN115868481A (zh) * | 2022-12-30 | 2023-03-31 | 嘉兴莱普晟医疗科技有限公司 | 一种用于保存胰腺的灌注***以及转运*** |
CN117269284B (zh) * | 2023-11-22 | 2024-02-27 | 中国人民解放军军事科学院军事医学研究院 | 携氧-释氧能力相对评价装置 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101897329A (zh) * | 2009-05-26 | 2010-12-01 | 四川大学华西医院 | 一种联合用心脏停跳保存液及其制备方法和应用 |
CN103430939A (zh) * | 2008-01-31 | 2013-12-11 | 特兰斯迈迪茨公司 | 用于离体肺护理的***和方法 |
CN105288627A (zh) * | 2015-09-17 | 2016-02-03 | 协和同仁科技(天津)有限责任公司 | 一种有携供氧功能的心脏停搏液与制备方法及其应用 |
CN107137699A (zh) * | 2017-06-15 | 2017-09-08 | 中国医学科学院输血研究所 | 一种天然血红蛋白类血液代用品的脱氧方法和制备工艺 |
CN110563836A (zh) * | 2019-09-09 | 2019-12-13 | 润方(北京)生物医药研究院有限公司 | 交联血红蛋白的制备方法及包含该血红蛋白的器官灌注液 |
-
2020
- 2020-04-24 CN CN202010332040.1A patent/CN111406737B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103430939A (zh) * | 2008-01-31 | 2013-12-11 | 特兰斯迈迪茨公司 | 用于离体肺护理的***和方法 |
CN101897329A (zh) * | 2009-05-26 | 2010-12-01 | 四川大学华西医院 | 一种联合用心脏停跳保存液及其制备方法和应用 |
CN105288627A (zh) * | 2015-09-17 | 2016-02-03 | 协和同仁科技(天津)有限责任公司 | 一种有携供氧功能的心脏停搏液与制备方法及其应用 |
CN107137699A (zh) * | 2017-06-15 | 2017-09-08 | 中国医学科学院输血研究所 | 一种天然血红蛋白类血液代用品的脱氧方法和制备工艺 |
CN110563836A (zh) * | 2019-09-09 | 2019-12-13 | 润方(北京)生物医药研究院有限公司 | 交联血红蛋白的制备方法及包含该血红蛋白的器官灌注液 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023196521A1 (en) * | 2022-04-06 | 2023-10-12 | Ohio State Innovation Foundation | Oxygen carriers for maintaining organ viability during normothermic perfusion |
Also Published As
Publication number | Publication date |
---|---|
CN111406737A (zh) | 2020-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111406737B (zh) | 用于器官持续维持的成分、装置和方法 | |
JP2962731B2 (ja) | 超純枠半合成代用血液 | |
JP5149480B2 (ja) | 高酸素親和性改変ヘモグロビンを含む、酸素輸送のための方法および組成物 | |
Vogel et al. | Coronary constrictor effect of stroma-free hemoglobin solutions | |
JP4382877B2 (ja) | 安定重合化ヘモグロビン代用血液 | |
US6506725B1 (en) | Ultra pure hemoglobin solutions and blood-substitutes | |
US5084558A (en) | Extra pure semi-synthetic blood substitute | |
ES2275712T3 (es) | Portadores de oxigeno artificiales de hemoglobina humana o porcina reticulada modificada, procedimientos para su preparacion a partir de material modificado y su uso. | |
US20130261061A1 (en) | Method of enhancing efficacy of blood transfusions | |
JPS63503381A (ja) | 合成の、血漿不含有で輸血可能な血小板貯蔵用媒質 | |
WO2014059316A1 (en) | Compositions and methods for organ preservation | |
MX2008014648A (es) | Metodos para tratar la anemia aguda por perdida de sangre con un sustituto de la sangre con hemoglobina reticulada. | |
JP4581110B2 (ja) | ヘモグロビンの精製方法 | |
US6894150B1 (en) | Non-pyrogenic, endotoxin-free, stroma-free tetrameric hemoglobin | |
Pearce et al. | HBOC-201 (hemoglobin glutamer-250)(bovine), hemopure®): clinical studies | |
CN111202050B (zh) | 一种常温机械器官灌注液及其制备方法 | |
US9572833B2 (en) | Treatment of red blood cells | |
Scatena et al. | O-raffinose-polymerised haemoglobin. A biochemical and pharmacological profile of an oxygen carrier | |
CN111357737B (zh) | 一种常温机械器官灌注液及其用途 | |
KRISHNA et al. | A review on artificial blood: a source we need | |
Tsuchida | Perspectives of blood substitutes | |
Dracker | The development and use of oxygen-carrying blood substitutes | |
CN114514034A (zh) | 稳定的血红蛋白组合物及其药物制剂 | |
US20240049700A1 (en) | Lipid layer preservation | |
Bartlett | Oxygen Therapeutics–The Quest for Artificial Blood |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220223 Address after: 101149 building 19, No. 99, Kechuang 14th Street, economic and Technological Development Zone, Daxing District, Beijing Patentee after: REDPHARM (BEIJING) BIOMEDICAL RESEARCH INSTITUTE Co.,Ltd. Patentee after: Runfang (Beijing) Biotechnology Co.,Ltd. Patentee after: You Kewei Address before: 101149 building 19, No. 99, Kechuang 14th Street, economic and Technological Development Zone, Daxing District, Beijing Patentee before: REDPHARM (BEIJING) BIOMEDICAL RESEARCH INSTITUTE Co.,Ltd. Patentee before: Runfang (Beijing) Biotechnology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230719 Address after: 101149 building 19, No. 99, Kechuang 14th Street, economic and Technological Development Zone, Daxing District, Beijing Patentee after: REDPHARM (BEIJING) BIOMEDICAL RESEARCH INSTITUTE Co.,Ltd. Patentee after: Runfang (Beijing) Biotechnology Co.,Ltd. Address before: 101149 building 19, No. 99, Kechuang 14th Street, economic and Technological Development Zone, Daxing District, Beijing Patentee before: REDPHARM (BEIJING) BIOMEDICAL RESEARCH INSTITUTE Co.,Ltd. Patentee before: Runfang (Beijing) Biotechnology Co.,Ltd. Patentee before: You Kewei |
|
TR01 | Transfer of patent right |